Till­man Gern­gross is­n't out to im­press you with biobucks, but here are 3 part­ner deals that should

Till­man Gern­gross doesn’t boast about every an­ti­body deal he does at Adimab. In fact, news of that kind is rel­a­tive­ly rare, con­sid­er­ing the 270 pro­grams they’ve worked on so far. But when the top play­ers in his field ei­ther sign on or ex­tend their pacts — hap­py with what they’ve seen so far — he’s not averse to spot­light­ing the ma­jor league en­dorse­ment that his com­pa­ny is de­liv­er­ing.

“I see this over and over again; the in­dus­try promis­ing and not de­liv­er­ing. And when we have a string of part­ner­ships with larg­er and more so­phis­ti­cat­ed buy­ers who want to con­tin­ue to work with us and ex­pand, that’s a val­i­da­tion — more than, ‘Well, I just found an­oth­er suck­er to sign on,’” says the out­spo­ken Dart­mouth pro­fes­sor.

These aren’t suck­ers he’s talk­ing about to­day. Re­gen­eron, wide­ly rec­og­nized as one of the most tal­ent­ed de­vel­op­ers of an­ti­bod­ies in the busi­ness, has signed up to ex­tend their long-run­ning re­la­tion­ship with Gern­gross’s com­pa­ny. No­var­tis is back as well. And Take­da, new­ly ex­pand­ed in Boston/Cam­bridge with their big Shire ac­qui­si­tion, is get­ting one of Adimab’s turnkey op­er­a­tions, which they’ll put to use in de­vel­op­ing their own pro­tein ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER